Navigation Links
Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Society's 57th Annual Meeting
Date:1/13/2011

tly less opioids were consumed over the first 24 hours after surgery in the EXPAREL group (p=0.0077);
  • EXPAREL was well tolerated in patients who received postsurgical treatment for pain following bunionectomy; 59.8% of patients treated with EXPAREL experienced an adverse event compared to 67.7% of patients treated with placebo;
  • Most of the adverse events were not considered related to study drug and were mild or moderate in severity.

  • The full poster can be found on the Pacira website at www.pacira.com.  

    In December 2010, Pacira announced that its New Drug Application (NDA) for EXPAREL had been accepted for filing by the U.S. Food and Drug Administration (FDA). Pacira submitted the EXPAREL NDA in September 2010 for the initial indication of postsurgical analgesia by local administration. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of July 28, 2011 for the review of the EXPAREL NDA.

    About EXPAREL™EXPAREL is Pacira's proprietary drug candidate consisting of bupivacaine encapsulated in DepoFoam®, both of which are currently used separately in FDA-approved products. Bupivacaine is a well-characterized anesthetic/analgesic that has an established safety profile with more than 20 years of use in the United States. Several Phase 2 and Phase 3 clinical trials have been completed for EXPAREL and demonstrate statistically significant reduction of pain in soft tissue and orthopedic surgery in different surgical models. Clinical data has also demonstrated that EXPAREL provides analgesia for up to 72 hours post-surgery compared with 7 hours or less for bupivacaine. The safety of EXPAREL was evaluated in 10 randomized, double-blind, local administration into the surgical wound clinical studies involving 823 patients; the most common adverse events following EXPAREL administration were nausea, constipation, and vomiting.  

    About PaciraPacira P
    '/>"/>

    SOURCE Pacira Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
    2. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
    3. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
    4. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
    5. Reportlinker Adds Watson Pharmaceuticals Inc.: PharmaVitae Profile
    6. Reportlinker Adds OTC Pharmaceuticals: Global Industry Almanac
    7. ADVENTRX Pharmaceuticals Announces Closing of $22.5 Million Financing
    8. Anadys Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
    9. Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors
    10. Topaz Pharmaceuticals Names Dr. Mark Strobeck Chief Business Officer
    11. Optimer Pharmaceuticals Announces Key Additions to Management Team
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/27/2015)... DUBLIN , July 27, 2015 /PRNewswire/ ... has announced the addition of the ... Competitors And Opportunities: 2015-2020 Analysis And Forecasts" ... Comprehensive information and evaluation of the ... analysis of manufacturers, segmentation, product offerings, competitive ...
    (Date:7/27/2015)...   DocResponse was ranked the most ... peer-reviewed study , "Evaluation of symptom checkers ... in the July issue of The British Medical ... School researchers determined that performance of online symptom ... diagnosis first in standardized patient evaluations more often ...
    (Date:7/27/2015)... 2015 Syneron Medical Ltd. ... market leader in the aesthetic medical device marketplace, announced ... and Drug Safety (MFDS) regulatory clearance for the PicoWay® ... fulfill PicoWay orders from its Korean distribution partner, with ... the third quarter 2015. Amit Meridor, Chief ...
    Breaking Medicine Technology:Global Wound Care Markets 2015-2020 - Traditonal, Advanced And Regenerative: Competitors And Opportunities 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 3Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 2Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 3Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 4
    ... Ortho-McNeil to Continue Investigation of GDIR Agonists Under its ... ... 7 Arena Pharmaceuticals, Inc.,(Nasdaq: ARNA ) announced today ... discovered by Arena and being investigated,for the treatment of type ...
    ... Phase 2 Program to Provide Initial Proof-of-Concept Data ... ... 7 VIA Pharmaceuticals,(Nasdaq: VIAP ), a biotechnology company focused ... today that,it has enrolled the first patient in its Phase 2 ...
    Cached Medicine Technology:Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes 2Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes 3Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes 4VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation 2VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation 3VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation 4VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation 5
    (Date:7/27/2015)... ... July 27, 2015 , ... At Champagne Smiles, they know that tooth ... can incur a lot of stress, pain, discomfort and embarrassment, which is why they ... treatment reaps the benefits of implants with the cost savings of dentures for anyone ...
    (Date:7/27/2015)... ... July 27, 2015 , ... Recently, 10 Best Water ... water brands also made the organization’s list. As its name clearly indicates, 10 Best ... Here is a description of the top three brands, along with a listing of ...
    (Date:7/27/2015)... ... ... In a creative effort to provide clear information about the process of ... Dove Tree in Lubbock has shared a new infographic to illustrate the process. The ... the nationally recognized collegiate program and traditional adult program at The Ranch at Dove ...
    (Date:7/27/2015)... ... July 27, 2015 , ... The new ... diagnostics applications is rapidly increasing and is driven by focused research of pharmaceutical ... increasingly being evaluated for use in bio implants. MWCNTs are used in the ...
    (Date:7/27/2015)... ... July 27, 2015 , ... SupplyLogic, a marketing execution ... on its newly redesigned company Website. In the blog, Founder and CEO Kevin Sherlock ... popular comedian: "Comedian George Wallace always asks: ‘Why is it the closer you get ...
    Breaking Medicine News(10 mins):Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 2Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 3Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 4Health News:Best Water Brand Awards Presented by 10 Best Water 2Health News:The Ranch At Dove Tree Infographic Enlightens Process Of Recovery 2Health News:The Ranch At Dove Tree Infographic Enlightens Process Of Recovery 3Health News:Fullerene Market to Grow at 13% CAGR to 2019 Says a New Research Report at Sandlerresearch.org 2Health News:Fullerene Market to Grow at 13% CAGR to 2019 Says a New Research Report at Sandlerresearch.org 3Health News:SupplyLogic Releases First Executive Blog on Supply Chain Management Issues 2
    ... and relationships have helped many children reduce their levels of ... in August 2005, according to a new study. A second ... in the aftermath of the storm. The studies appear ... July/August 2010 issue of the journal Child Development . ...
    ... who survived the 2004 tsunami and ongoing civil war there ... to the youths, psychological health, but also daily stressors like ... after the disasters. The studies appear in a special ... of the journal Child Development . The first ...
    ... University of Texas MD Anderson Cancer Center remains the leading hospital ... according to the annual "Best Hospitals" survey published by U.S. News ... last nine years that MD Anderson has ranked number one in ... has been ranked one of the top two cancer hospitals in ...
    ... milk be avoided in the early months of an infant,s ... until baby starts eating solid food. But new research from ... cow,s milk in the first 15 days of life may ... Prof. Yitzhak Katz of Tel Aviv University,s Department of Pediatrics, ...
    ... Steven Reinberg HealthDay Reporter , WEDNESDAY, July 14 ... helps people drop pounds but does so with few side ... fighting the obesity epidemic, lorcaserin is a new type of ... associated with feelings of well-being and feeling full, and does ...
    ... HealthDay Reporter , WEDNESDAY, July 14 (HealthDay News) ... for Alzheimer,s disease for the first time in 25 years ... key change would put more focus on the various stages ... convened by the U.S. National Institute on Aging and the ...
    Cached Medicine News:Health News:Hurricane Katrina's effects on children: Resilience and gender 2Health News:Sri Lankan children affected by war, tsunami, daily stressors 2Health News:MD Anderson keeps No. 1 cancer ranking in US News & World Report annual survey 2Health News:MD Anderson keeps No. 1 cancer ranking in US News & World Report annual survey 3Health News:Cow's milk does a baby good 2Health News:New Pill Found to Cut Weight With Few Side Effects: Study 2Health News:New Pill Found to Cut Weight With Few Side Effects: Study 3Health News:New Criteria for Alzheimer's Diagnosis Proposed 2Health News:New Criteria for Alzheimer's Diagnosis Proposed 3
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    Medicine Products: